A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer
Phase II Study to Assess the Efficacy of Durvalumab (MEDI4736) and Tremelimumab Plus Radiotherapy or Ablation in Patients With Metastatic Colorectal Cancer
Sponsor: AstraZeneca
A PHASE2 clinical study on Metastatic Colorectal Cancer, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 14 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Sep 2022 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 9 earlier versions
-
May 2021 — Sep 2022 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Apr 2021 — May 2021 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2019 — Mar 2020 [monthly]
Recruiting PHASE2
-
Nov 2018 — Jun 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE2
-
Jun 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
May 2017 — Jun 2017 [monthly]
Recruiting PHASE2
First recorded
Apr 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- MedImmune LLC
- Memorial Sloan Kettering Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .